Detalhe da pesquisa
1.
Strategies to increase primary care provider capacity for hepatitis C care: The California ECHO-PLUS study.
J Viral Hepat
; 30(5): 397-405, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36696286
2.
The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.
Antimicrob Agents Chemother
; 58(10): 6145-50, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25092710
3.
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.
Antimicrob Agents Chemother
; 57(6): 2654-63, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23529738
4.
Comparing Hepatitis C Virus Screening in Clinics Versus the Emergency Department.
West J Emerg Med
; 23(3): 312-317, 2022 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35679493
5.
Pharmacist Intervention Lowers HgbA1c in Diabetic Patients Regardless of HIV Status.
J Pharm Pract Res
; 51(4): 307-313, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34539238
6.
Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
Bioorg Med Chem Lett
; 18(3): 1131-4, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18083512
7.
De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents.
Hepat Oncol
; 5(1): HEP06, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30302197
8.
In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
Antiviral Res
; 93(2): 288-296, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22197635